Arovella receives R&D tax incentive and new advisory board
Arovella Therapeutics (ASX:ALA) has recently released its quarterly report, announcing the receipt of a $3.0 million Research and Development (R&D) Tax Incentive refund, with an additional $0.3 million expected shortly. This funding enhances Arovella’s financial position as it advances its lead asset, ALA-101, towards first-in-human clinical trials. CEO Dr Michael Baker stated, “The R&D Tax […]
Arovella receives R&D tax incentive and new advisory board Read More »